Navigation Links
iZumi Bio and Kyoto University Form Collaboration to Advance Induced Pluripotent Stem Cell Technology
Date:4/14/2009

Former Vice President Al Gore Endorses Trans-Pacific Collaboration to Promote Use of Patient Cells for Drug Discovery and Development and Cell-Based Therapies

SOUTH SAN FRANCISCO, Calif., and KYOTO, Japan, April 14 /PRNewswire/ -- iZumi Bio, Inc., and Kyoto University's Center for iPS Cell Research and Application (CiRA), today announced a collaboration to promote the basic research, development and application of induced pluripotent stem (iPS) cell technology - a form of cellular reprogramming which originated in Japan - with the goal of advancing drug discovery and enabling cell-based therapies.

"Stem cell research holds great promise for the creation of new therapies that could revolutionize the treatment of disorders such as Parkinson's disease, diabetes and muscular dystrophy. The discovery that iPS cell technology brings, that "stem cell-like" cells can be generated from a small amount of human skin rather than from embryos, opens a new door for stem cell research and its application to therapeutic discovery," said Al Gore, former Vice President of the United States and a partner at venture capital firm Kleiner Perkins Caufield and Byers. Noting that Science Magazine named cellular reprogramming the "breakthrough of the year" in 2008, Gore concluded, "The partnership between these two leading organizations is a critical step in furthering this research and turning stem cell research into therapeutic realities sooner."

Through the collaboration, iZumi and CiRA will exchange part of their representative human iPS cell lines derived by various methods. The two organizations also will conduct comparison and characterization studies independently but will share their results to determine which methods produce the most appropriate iPS cell lines for drug screening and development, and those most suitable for cell-based therapy.

"This collaboration, which is focused on t
'/>"/>

SOURCE iZumi Bio, Inc.; Kyoto University
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. University of Iowa professor identifies new eating disorder
2. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
3. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
4. Tulane University to receive $14M for international HIV/AIDS program
5. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
6. Boston University School of Medicine researcher recipient of Memory Ride Grant
7. Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Womens Services Programs and Departments
8. Medina General Hospital and University Hospitals Agree to Pursue Affiliation
9. J.D. Power and Associates Reports: Hackensack University Medical Center Recognized as First Hospital to Achieve Distinction for Providing an Outstanding Inpatient Experience in All Four Service Areas
10. The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers
11. George Mason University professor receives $2.6 million NIH grant to study Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... 23, 2014 A team of New York ... longer when preceded by surgery and delivered by an experienced ... new study. Click here to read it now . ... cases of mesothelioma patients who underwent hemithoracic (one ... dose to the shape of a tumor. Patients who ...
(Date:8/23/2014)... 23, 2014 GBI Research, the leading ... Care Therapeutics in Major Developed Markets to 2020 - ... Drive Market”, which provides in-depth analysis of the critical ... Spain, Japan and Canada. The report provides an estimation ... to 2020. It covers critical care indications that are ...
(Date:8/23/2014)... Young adults in Athens, GA who find that they ... the phone and call the new helpline which can offer support ... , Troubled Teen Athens is a wonderful resource for an adolescent ... necessary steps to end substance abuse once and for all. When ... friends or peers when really they should put their faith in ...
(Date:8/23/2014)... NC (PRWEB) August 23, 2014 Teen substance ... young people in Holly Springs, NC. Countless adolescents throughout North ... regular basis. Unfortunately, many never receive professional rehab due ... adults on where to get help. Troubled Teens Holly Springs ... the lives of local teenage alcohol abusers in ...
(Date:8/22/2014)... 2014 2014 Deep Research Report ... and in-depth research report on the Glucose Meter ... including Glucose Meter definition, classification, application, and industry ... research covers the international market analysis, including domestic ... macroeconomic environment & economic situation analysis. The report ...
Breaking Medicine News(10 mins):Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3Health News:Teenagers in Athens, GA are Locating Addiction Recovery Thanks to New Helpline 2Health News:New Helpline Provides Teen Drug & Alcohol Recovery Information in Holly Springs, NC 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 3
... IRVINE, Calif., June 26 ISTA Pharmaceuticals, Inc. (Nasdaq: ... Ophthalmic Drugs Advisory Committee appointed by the U.S. Food ... (bepotastine besilate ophthalmic solution) 1.5% as an eye drop ... The Committee voted unanimously 7 to 0 in favor ...
... Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ), ... information in regards to our financial position in light of ... to the FDA action are currently being identified. The early ... $15 to $20 million. , , The products subject ...
... announced today that it will hold its 2009 Annual General ... Meeting of Shareholders (the "Special Meeting") on August 5, 2009. ... asked to vote in favor of certain matters related to ... Subject to shareholder approval and the approval of the ...
... , CASTRES, France, June ... Committee for Medicinal Products for Human Use,(CHMP), the ... has issued a positive opinion supporting approval and ... monotherapy in metastatic,treatment of bladder cancer (advanced or ...
... June 26 Today Sentry Data Systems, Inc. announced ... Pharmacy and Revenue Cycle Management application. Claims Guardian ... their bills for unusual, missing, or errant charges that ... , "We believe that automatically matching actual procurement ...
... Healthcare ... the second straight year. The list is sponsored by the Greater Omaha Chamber of Commerce and ... , ... Healthcare staffing company Medical Solutions has landed on the Best Places to ...
Cached Medicine News:Health News:Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 2Health News:Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Updates on Financial Position 2Health News:Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders 2Health News:Positive CHMP Opinion for JAVLOR(R) in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum-Containing Regimen 2Health News:Positive CHMP Opinion for JAVLOR(R) in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum-Containing Regimen 3Health News:Sentry Data Systems Announces Claims Guardian(TM) 2Health News:Sentry Data Systems Announces Claims Guardian(TM) 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 2Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 4
(Date:8/22/2014)... Calif. , Aug. 22, 2014  WaferGen Bio-systems, ... underwritten public offering of units of common stock and ... gross proceeds of $20 million, prior to deducting underwriting ... Company.  The shares and warrants are immediately separable and ... are expected to begin trading on The NASDAQ Stock ...
(Date:8/21/2014)... 21, 2014   Memorial Hermann Health System and ... today announced a new partnership to provide a new level ... care centers in the greater Houston ... become the exclusive provider of professional breast radiology services for ... Memorial City, The Woodlands , Northeast, Southwest ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
Spoon end periosteal, polished finish, designed for large mucoperiosteal flaps....
Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm)....
Key periosteal elevators, blade width 1" (25 mm), total length 7 1/2" (191 mm)....
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
Medicine Products: